[{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sun Yat-sen University \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Fudan University","sponsor":"Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People\u2019s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People\u2019s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio","highestDevelopmentStatusID":"10","companyTruncated":"Fudan University \/ Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People\u2019s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio"},{"orgOrder":0,"company":"Peking University","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Peking University \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Peking University","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Peking University \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sun Yat-sen University \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Japan Clinical Cancer Research Organization","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Japan Clinical Cancer Research Organization","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Clinical Cancer Research Organization \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Japan Clinical Cancer Research Organization \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"National Cancer Centre, Singapore","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"National Taiwan University Hospital \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"6","companyTruncated":"National Taiwan University Hospital \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"Medigen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Taiho Pharmaceutical | Nordic Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ Taiho Pharmaceutical | Nordic Pharma","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ Taiho Pharmaceutical | Nordic Pharma"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Nordic Pharma | Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ Nordic Pharma | Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ Nordic Pharma | Taiho Pharmaceutical"},{"orgOrder":0,"company":"Dutch Colorectal Cancer Group","sponsor":"Nordic Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Dutch Colorectal Cancer Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dutch Colorectal Cancer Group \/ Nordic Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Dutch Colorectal Cancer Group \/ Nordic Pharma"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celgene Corporation"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Oncology \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Sinoflurol
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CD...
Details :
Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.
Details :
The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.
Sponsor :
Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Sponsor :
Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Sponsor :
Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People’s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.
Sponsor :
Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People’s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio
Details :
Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.
Reset All
